Response to dabrafenib plus trametinib on a rare BRAF mutation (V600_W604 deletion-insertion R) in an advanced non-small cell lung cancer patient.
Thorac Cancer
; 15(18): 1454-1456, 2024 Jun.
Article
en En
| MEDLINE
| ID: mdl-38766698
ABSTRACT
Although dabrafenib plus trametinib has been approved for BRAF V600E mutation positive advanced non-small cell lung cancer (NSCLC), data on its efficacy against uncommon BRAF mutations are still limited due to their rare frequency. We report a case of 70-year-old woman with BRAF V600_W604 deletion-insertion R-positive stage IVA lung adenocarcinoma, who was successfully treated with dabrafenib plus trametinib. Herein, we discuss the oncogenic role of uncommon BRAF mutations and highlight the importance of performing comprehensive genomic profiling on patients without any targetable gene alterations in companion diagnostics.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Oximas
/
Piridonas
/
Pirimidinonas
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Carcinoma de Pulmón de Células no Pequeñas
/
Proteínas Proto-Oncogénicas B-raf
/
Imidazoles
/
Neoplasias Pulmonares
Límite:
Aged
/
Female
/
Humans
Idioma:
En
Revista:
Thorac Cancer
Año:
2024
Tipo del documento:
Article
País de afiliación:
Japón
Pais de publicación:
Singapur